{"id":78775,"date":"2026-09-04T16:22:34","date_gmt":"2026-09-04T08:22:34","guid":{"rendered":"https:\/\/flcube.com\/?p=78775"},"modified":"2026-09-04T16:22:35","modified_gmt":"2026-09-04T08:22:35","slug":"abbvies-etentamig-delivers-positive-phase-iii-cervino-results-in-triple-class-exposed-relapsed-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78775","title":{"rendered":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>)<\/strong> announced positive topline results from the <strong>Phase III CERVINO study<\/strong> evaluating <strong>etentamig<\/strong>, an investigational <strong>BCMA x CD3 bispecific T-cell engager<\/strong>, versus standard available therapies (SAT) in patients with <strong>triple-class exposed relapsed\/refractory multiple myeloma (RRMM)<\/strong> \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions <strong>AbbVie\u2019s<\/strong> second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.<\/p>\n\n\n\n<h2 id=\"h-study-overview\" class=\"wp-block-heading\">Study Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Sponsor<\/td><td><strong>AbbVie (NYSE: ABBV)<\/strong><\/td><\/tr><tr><td>Product<\/td><td><strong>etentamig<\/strong> (investigational)<\/td><\/tr><tr><td>Study<\/td><td><strong>CERVINO<\/strong>, Phase III<\/td><\/tr><tr><td>Design<\/td><td>Etentamig versus <strong>standard available therapies (SAT)<\/strong><\/td><\/tr><tr><td>Population<\/td><td><strong>Triple-class exposed<\/strong> relapsed\/refractory multiple myeloma (proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody)<\/td><\/tr><tr><td>Result<\/td><td>Positive topline results<\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>etentamig<\/strong>, an investigational, <strong>second-generation BCMA x CD3 bispecific antibody T-cell engager<\/strong><\/li>\n\n\n\n<li><strong>Design Goal:<\/strong> Combine meaningful anti-myeloma activity with a differentiated treatment experience for patients<\/li>\n\n\n\n<li><strong>Key Structural Features:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Low-affinity CD3 binding domain<\/strong> \u2014 designed to reduce cytokine release syndrome (CRS) and infections<\/li>\n\n\n\n<li><strong>High-avidity bivalent BCMA-binding domain<\/strong> \u2014 for potent target engagement on myeloma cells<\/li>\n\n\n\n<li><strong>Retained FcRn binding<\/strong> \u2014 enabling <strong>monthly (Q4W) dosing<\/strong> after a single step-up dose<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Caution:<\/strong> Clinical correlations of these structure-activity relationships have <strong>not been fully established<\/strong>; the CERVINO data will be central to validating the design hypothesis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-cervino\" class=\"wp-block-heading\">Clinical Evidence \u2013 CERVINO<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The <strong>CERVINO<\/strong> study produced <strong>positive topline results<\/strong> for etentamig versus standard available therapies in triple-class exposed RRMM patients<\/li>\n\n\n\n<li>The comparator arm reflects real-world practice, as patients who have progressed through the three dominant drug classes face limited and generally poor-performing remaining options<\/li>\n\n\n\n<li>Detailed efficacy and safety data from the study are expected to be presented at a future medical meeting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-need segment:<\/strong> Triple-class exposed RRMM represents a rapidly growing population as patients survive longer through successive lines of therapy, with few effective options remaining<\/li>\n\n\n\n<li><strong>Differentiation potential:<\/strong> If the engineered safety profile and monthly dosing are confirmed clinically, <strong>etentamig<\/strong> could offer a treatment experience advantage over first-generation bispecifics that require more frequent dosing and carry higher CRS risk<\/li>\n\n\n\n<li><strong>Competitive landscape:<\/strong> The result strengthens <strong>AbbVie\u2019s<\/strong> position in a crowded bispecific field targeting BCMA, where dosing convenience and tolerability are increasingly decisive commercial differentiators<\/li>\n\n\n\n<li><strong>Portfolio momentum:<\/strong> The positive Phase III readout adds to <strong>AbbVie\u2019s<\/strong> (NYSE: ABBV) expanding hematology-oncology pipeline beyond its legacy franchises<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding clinical potential, regulatory submissions and market opportunity are forward-looking and subject to risks and uncertainties, including full data interpretation, regulatory decisions and competitive developments. Clinical correlations of etentamig\u2019s structure-activity design have not been fully established. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,16,17,853,2790],"class_list":["post-78775","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbvie","tag-cancer","tag-clinical-trial-results","tag-nyse-abbv","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78775\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78775\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:22:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:22:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\\\/Refractory Multiple Myeloma\",\"datePublished\":\"2026-09-04T08:22:34+00:00\",\"dateModified\":\"2026-09-04T08:22:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Cancer\",\"Clinical trial results\",\"NYSE: ABBV\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78775#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78775\",\"name\":\"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\\\/Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:22:34+00:00\",\"dateModified\":\"2026-09-04T08:22:35+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\\\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78775\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78775#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\\\/Refractory Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78775","og_locale":"en_US","og_type":"article","og_title":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","og_description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.","og_url":"https:\/\/flcube.com\/?p=78775","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:22:34+00:00","article_modified_time":"2026-09-04T08:22:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78775#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78775"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","datePublished":"2026-09-04T08:22:34+00:00","dateModified":"2026-09-04T08:22:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78775"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Cancer","Clinical trial results","NYSE: ABBV","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78775#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78775","url":"https:\/\/flcube.com\/?p=78775","name":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:22:34+00:00","dateModified":"2026-09-04T08:22:35+00:00","description":"AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed\/refractory multiple myeloma (RRMM) \u2014 patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie\u2019s second-generation bispecific as a potential new option in one of hematologic oncology\u2019s most difficult-to-treat populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78775#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78775"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78775#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie\u2019s Etentamig Delivers Positive Phase III CERVINO Results in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78775"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78775\/revisions"}],"predecessor-version":[{"id":78776,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78775\/revisions\/78776"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}